Mechanisms of Action against NAFLD/NASH and Liver Fibrosis
Chronic liver diseases (CLDs)—ranging from steatosis to fibrosis and cirrhosis—remain a clinical challenge due to the limited availability of effective and well-tolerated treatments. A review published in Molecules (March 11, 2025) compiles preclinical evidence on three key natural compounds: baicalein, galangin, and isorhamnetin. The underlying theme is clear: antioxidant, anti-inflammatory, and anti-fibrotic actions, with positive effects on lipid metabolism, fibrogenesis, and the gut–liver axis.
These flavonoids share a common structural framework (C2–C3 unsaturation and C4 carbonyl group) that enhances free radical scavenging and the modulation of crucial cellular response pathways. The result is hepatoprotection that, in animal and cell models, translates into reduced steatosis, controlled inflammation, and slowed fibrotic progression.
Key Mechanisms
- Oxidative stress and inflammation: Activation of NRF2/HO-1 and concurrent inhibition of NF-κB lead to decreased ROS/RNS and pro-inflammatory cytokines.
- Metabolism and fibrosis: AMPK↑/SREBP1↓ reduces lipogenesis; modulation of TGF-β/Smad and balancing of MMP/TIMP limit hepatic stellate cell activation, while restoring gut eubiosis (FXR, LPS↓).
Baicalein: Controlling Steatosis and NASH
Extracted from Scutellaria baicalensis, baicalein exhibits dual protective actions. In NAFLD/NASH models, it reduces lipid accumulation and liver injury by activating AMPK and enhancing NRF2/HO-1; in cholestatic models (bile duct ligation), it downregulates profibrotic markers and improves mitochondrial function.
Its metabolite baicalin—more soluble and strongly bound to albumin—shares many of these effects. In its baicalin–magnesium formulation, preclinical efficacy increases thanks to improved solubility.
Galangin: Autophagy as an Ally
Found in galangal (Alpinia officinarum) and propolis, galangin mitigates NAFLD both preventively and therapeutically, reducing liver enzymes, lipids, and tissue damage through autophagy-dependent mechanisms (its inhibition weakens protection).
In fibrosis models, galangin inhibits hepatic stellate cell activation (α-SMA, collagen) and promotes apoptosis (Bax/Bcl-2 ratio), while in vitro it shows anti-metastatic activity via PKC/ERK and MMP-2/9 modulation. In alcoholic liver disease, its benefits are linked to gut–liver axis regulation.
Isorhamnetin: A Precision Anti-Fibrotic Agent
A methylated derivative of quercetin (BCS II: high permeability, low solubility), isorhamnetin inhibits TGF-β/Smad (↓p-Smad2/3), activates NRF2, restores glutathione, and reduces lipogenesis (SREBP1c, FAS). In NASH models, it improves histology, lipid profiles, and damage biomarkers; in CCl₄/BDL models, it lowers collagen and α-SMA levels and restores extracellular matrix balance (MMP-2/TIMP1).
Sources and Natural Forms
Baicalein/baicalin are derived from Scutellaria baicalensis; galangin comes from galangal and propolis; isorhamnetin is abundant in onions, apples, pears, sea buckthorn, green tea, berries, and prickly pear. These compounds naturally occur as glycosides (e.g., baicalin, isorhamnetin-3-O-glucoside), which influence absorption, metabolism, and enterohepatic circulation.
Limitations and Implications
Predominantly preclinical evidence: Effective in vitro concentrations are not physiologically achievable in vivo; animal models and experimental protocols vary significantly, complicating comparisons.
Bioavailability issues: Poor solubility and extensive first-pass metabolism limit systemic exposure; advanced formulations (nanocarriers, complex salts) and clinical trials with robust endpoints are needed.
The baicalein–galangin–isorhamnetin trio emerges as a multitarget approach for CLDs, acting on steatosis, inflammation, and fibrogenesis, with the gut microbiota as an amplifier. Clinically, their role is potentially adjunctive, not a replacement for standard therapies. Synergy with the Mediterranean diet and precision medicine strategies represents a promising avenue for future research.
This review outlines three molecules that share a common biological mission: reducing oxidative stress, rebalancing metabolism, and halting pathological scarring. The promise is substantial, but the decisive step remains clinical translation. Clarified pharmacokinetics, optimized formulations, and well-designed controlled trials will determine whether these flavonoids can truly change the natural history of chronic liver diseases.
If your company wants to create or manufacture a product for the management of chronic liver diseases:
Source: March 2025, “Preventive and Therapeutic Effects of Baicalein, Galangin, and Isorhamnetin in Chronic Liver Diseases: A Narrative Review”, MDPI
